DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
LUPER
A Phase 1/2 Trial of Lurbinectedin (L) in Combination with Pembrolizumab (P) in Relapsed Small Cell Lung Cancer (SCLC): The LUPER Study.
LUNG
ASCO
2022
PHERGAIN
Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
BREAST
ESMO Breast
2022
ATRACTIB
Safety Interim Analysis (SIA) of ATRACTIB: A Phase 2 Trial of First-Line (1L) Atezolizumab (A) in Combination with Paclitaxel (P) and Bevacizumab (B) in Metastatic Triple-Negative Breast Cancer (mTNBC).
BREAST
ASCO
2022
EXCAAPE
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial
PROSTATE
(Journal) European Journal of Cancer
2022
PHERGAIN
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study
BREAST
(Journal) Future Oncology
2022
PARSIFAL
PD13-10 – Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2-ABC): Exploratory Analysis of the PARSIFAL Trial
BREAST
SABCS
2022
COPERNICO
Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study
COVID-19
(Journal) International Journal of Infectious Disease
2022
ATRACTIB
ATRACTIB: A Phase 2 Trial of First-Line (1L) Atezolizumab (A) in Combination with Paclitaxel (P) and Bevacizumab (B) in Metastatic Triple-Negative Breast Cancer (mTNBC)
BREAST
ESMO Breast
2022
OPHELIA
Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advancewd Breast Cancer Patients: The OPHELIA Study.
BREAST
SABCS
2022
DEBBRAH
Trastuzumab deruxtecan (T-DXd; DS-8201) en pacientes con cáncer de mama metastásico HER2-positivo o con baja expresión de HER2 con metástasis cerebrales y/o carcinomatosis leptomeníngea: Estudio DEBBRAH
BREAST
SEOM
2021
PATHFINDER
Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer: Pathfinder trial
BREAST
ESMO
2021
DEBBRAH
Trastuzumab Deruxtecan (DS-8201) in HER2-Positive and HER2-Low Expressing Metastatic Breast Cancer with Brain Metastases and/or Leptomeningeal Carcinomatosis: DEBBRAH
BREAST
ESMO
2021
Other MEDSIR related articles
